BAFF- and APRIL-targeted Therapy in Systemic Autoimmune Diseases

Overview

Journal Inflamm Regen

Publisher Biomed Central

Date 2017 Dec 21

PMID 29259679

Citations 27

Authors

Shingo Nakayamada

Yoshiya Tanaka

Affiliations

Soon will be listed here.

Abstract

B cells play a pivotal role in autoimmunity not only by producing pathogenic autoantibodies but also by modulating immune responses via the production of cytokines and chemokines. The B cell-activating factor/a proliferation-inducing ligand (BAFF/APRIL) system promotes B cell survival and differentiation and thus plays a prominent role in the pathogenesis of autoimmune diseases. Currently, BAFF and APRIL inhibitors are in clinical trials for systemic lupus erythematosus with significant efficacy. However, several studies have demonstrated the efficacy of the BAFF/APRIL blockade which showed considerable variability in the response to B cell-targeted therapy. This may indicate substantial heterogeneity in the pathogenesis of autoimmune diseases. Therefore, objective markers that can predict the effect of BAFF/APRIL-blocking agents could be valuable to the precision medicine linked clinically and to cost-effective therapy.

Citing Articles

Systemic lupus erythematosus: pathogenesis and targeted therapy.

Su X, Yu H, Lei Q, Chen X, Tong Y, Zhang Z Mol Biomed. 2024; 5(1):54.

PMID: 39472388 PMC: 11522254. DOI: 10.1186/s43556-024-00217-8.

Immune Dysregulation in the Oral Cavity during Early SARS-CoV-2 Infection.

Graves C, Babikow E, Ghaltakhchyan N, Ngo T, Liu C, Wang S J Dent Res. 2024; 103(12):1258-1270.

PMID: 39394771 PMC: 11562286. DOI: 10.1177/00220345241271943.

Causal association between peripheral immune cells and IgA nephropathy: a Mendelian randomization study.

Liang L, Xiong L, He X, Song L, Wang X, Lu Y Front Immunol. 2024; 15:1371662.

PMID: 39221249 PMC: 11361932. DOI: 10.3389/fimmu.2024.1371662.

Drugs in Development to Treat IgA Nephropathy.

Del Vecchio L, Allinovi M, Comolli S, Peiti S, Rimoldi C, Locatelli F Drugs. 2024; 84(5):503-525.

PMID: 38777962 DOI: 10.1007/s40265-024-02036-1.

B cell pathway dual inhibition for systemic lupus erythematosus: a prospective single-arm cohort study of telitacicept.

Ji L, Geng Y, Zhang X, Deng X, Song Z, Tan M MedComm (2020). 2024; 5(4):e515.

PMID: 38525109 PMC: 10960726. DOI: 10.1002/mco2.515.

References

Manzi S, Sanchez-Guerrero J, Merrill J, Furie R, Gladman D, Navarra S . Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012; 71(11):1833-8. PMC: 3465857. DOI: 10.1136/annrheumdis-2011-200831. View

Sanz I, Lee F . B cells as therapeutic targets in SLE. Nat Rev Rheumatol. 2010; 6(6):326-37. PMC: 3934759. DOI: 10.1038/nrrheum.2010.68. View

Blair P, Norena L, Flores-Borja F, Rawlings D, Isenberg D, Ehrenstein M . CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity. 2010; 32(1):129-40. DOI: 10.1016/j.immuni.2009.11.009. View

Vinuesa C, Cook M, Angelucci C, Athanasopoulos V, Rui L, Hill K . A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature. 2005; 435(7041):452-8. DOI: 10.1038/nature03555. View

Gregersen J, Jayne D . B-cell depletion in the treatment of lupus nephritis. Nat Rev Nephrol. 2012; 8(9):505-14. DOI: 10.1038/nrneph.2012.141. View

Mackay F, Schneider P, Rennert P, Browning J . BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol. 2002; 21:231-64. DOI: 10.1146/annurev.immunol.21.120601.141152. View

Avalos A, Busconi L, Marshak-Rothstein A . Regulation of autoreactive B cell responses to endogenous TLR ligands. Autoimmunity. 2009; 43(1):76-83. PMC: 3059585. DOI: 10.3109/08916930903374618. View

Bossen C, Schneider P . BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol. 2006; 18(5):263-75. DOI: 10.1016/j.smim.2006.04.006. View

Nagafuchi H, Atsumi T, Hatta K, Muso E, Takeno M, Yamada H . Long-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis. Mod Rheumatol. 2014; 25(4):603-8. DOI: 10.3109/14397595.2014.981945. View

10.

Tangye S, Ma C, Brink R, Deenick E . The good, the bad and the ugly - TFH cells in human health and disease. Nat Rev Immunol. 2013; 13(6):412-26. DOI: 10.1038/nri3447. View

11.

Mackay F, Ambrose C . The TNF family members BAFF and APRIL: the growing complexity. Cytokine Growth Factor Rev. 2003; 14(3-4):311-24. DOI: 10.1016/s1359-6101(03)00023-6. View

12.

Shulga-Morskaya S, Dobles M, Walsh M, Ng L, Mackay F, Rao S . B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J Immunol. 2004; 173(4):2331-41. DOI: 10.4049/jimmunol.173.4.2331. View

13.

Navarra S, Guzman R, Gallacher A, Hall S, Levy R, Jimenez R . Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011; 377(9767):721-31. DOI: 10.1016/S0140-6736(10)61354-2. View

14.

Schwartzberg P, Mueller K, Qi H, Cannons J . SLAM receptors and SAP influence lymphocyte interactions, development and function. Nat Rev Immunol. 2008; 9(1):39-46. DOI: 10.1038/nri2456. View

15.

Linterman M, Rigby R, Wong R, Yu D, Brink R, Cannons J . Follicular helper T cells are required for systemic autoimmunity. J Exp Med. 2009; 206(3):561-76. PMC: 2699132. DOI: 10.1084/jem.20081886. View

16.

Jacob C, Pricop L, Putterman C, Koss M, Liu Y, Kollaros M . Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF. J Immunol. 2006; 177(4):2671-80. PMC: 2896675. DOI: 10.4049/jimmunol.177.4.2671. View

17.

Nakayamada S, Saito K, Nakano K, Tanaka Y . Activation signal transduction by beta1 integrin in T cells from patients with systemic lupus erythematosus. Arthritis Rheum. 2007; 56(5):1559-68. DOI: 10.1002/art.22581. View

18.

Lutalo P, DCruz D . Biological drugs in ANCA-associated vasculitis. Int Immunopharmacol. 2015; 27(2):209-12. DOI: 10.1016/j.intimp.2015.04.023. View

19.

Iwata S, Saito K, Tokunaga M, Yamaoka K, Nawata M, Yukawa S . Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab. J Rheumatol. 2010; 38(4):633-41. DOI: 10.3899/jrheum.100729. View

20.

Nagai M, Hirayama K, Ebihara I, Shimohata H, Kobayashi M, Koyama A . Serum levels of BAFF and APRIL in myeloperoxidase anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis: association with disease activity. Nephron Clin Pract. 2011; 118(4):c339-45. DOI: 10.1159/000323393. View